In this study, to obtain more specific and useful information about the response to temozolomide and the actual clinical course, we focused on the volume change of residual tumor and statistically examined the relationship between MGMT promoter methylation percentage (MGMTpm%) and response to temozolomide or survival. This evidence concerns the gene MGMT and neoplasm.